EP2534136A4 - Procedes et appareil pour effectuer la synthese d'agents d'imagerie et leurs intermediaires - Google Patents

Procedes et appareil pour effectuer la synthese d'agents d'imagerie et leurs intermediaires

Info

Publication number
EP2534136A4
EP2534136A4 EP11740546.4A EP11740546A EP2534136A4 EP 2534136 A4 EP2534136 A4 EP 2534136A4 EP 11740546 A EP11740546 A EP 11740546A EP 2534136 A4 EP2534136 A4 EP 2534136A4
Authority
EP
European Patent Office
Prior art keywords
intermediates
methods
imaging agents
synthesizing imaging
synthesizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11740546.4A
Other languages
German (de)
English (en)
Other versions
EP2534136A2 (fr
EP2534136B1 (fr
Inventor
Richard R Cesati
Edward H Cheesman
Joel Lazewatsky
Heike S Radeke
James F Castner
Enrico Mongeau
Dianne D Zdankiewicz
Robert Wilburn Siegler
Marybeth Devine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Priority to EP17189439.7A priority Critical patent/EP3323810B1/fr
Priority to EP21216335.6A priority patent/EP4046990A1/fr
Priority to DK17189439.7T priority patent/DK3323810T3/da
Publication of EP2534136A2 publication Critical patent/EP2534136A2/fr
Publication of EP2534136A4 publication Critical patent/EP2534136A4/fr
Application granted granted Critical
Publication of EP2534136B1 publication Critical patent/EP2534136B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cameras In General (AREA)
EP11740546.4A 2010-02-08 2011-02-08 Procedes pour effectuer la synthese d'agents d'imagerie et leurs intermediaires Active EP2534136B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17189439.7A EP3323810B1 (fr) 2010-02-08 2011-02-08 Système de réaction automatisé, cassette et appareil pour la synthèse d'agents d'imagerie
EP21216335.6A EP4046990A1 (fr) 2010-02-08 2011-02-08 Procédés et appareil pour la synthèse d'agents d'imagerie et leurs intermédiaires
DK17189439.7T DK3323810T3 (da) 2010-02-08 2011-02-08 Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30247710P 2010-02-08 2010-02-08
US31537610P 2010-03-18 2010-03-18
US33369310P 2010-05-11 2010-05-11
PCT/US2011/024109 WO2011097649A2 (fr) 2010-02-08 2011-02-08 Procedes et appareil pour effectuer la synthese d'agents d'imagerie et leurs intermediaires

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21216335.6A Division EP4046990A1 (fr) 2010-02-08 2011-02-08 Procédés et appareil pour la synthèse d'agents d'imagerie et leurs intermédiaires
EP17189439.7A Division EP3323810B1 (fr) 2010-02-08 2011-02-08 Système de réaction automatisé, cassette et appareil pour la synthèse d'agents d'imagerie

Publications (3)

Publication Number Publication Date
EP2534136A2 EP2534136A2 (fr) 2012-12-19
EP2534136A4 true EP2534136A4 (fr) 2013-07-24
EP2534136B1 EP2534136B1 (fr) 2017-09-06

Family

ID=44356121

Family Applications (3)

Application Number Title Priority Date Filing Date
EP17189439.7A Active EP3323810B1 (fr) 2010-02-08 2011-02-08 Système de réaction automatisé, cassette et appareil pour la synthèse d'agents d'imagerie
EP21216335.6A Pending EP4046990A1 (fr) 2010-02-08 2011-02-08 Procédés et appareil pour la synthèse d'agents d'imagerie et leurs intermédiaires
EP11740546.4A Active EP2534136B1 (fr) 2010-02-08 2011-02-08 Procedes pour effectuer la synthese d'agents d'imagerie et leurs intermediaires

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP17189439.7A Active EP3323810B1 (fr) 2010-02-08 2011-02-08 Système de réaction automatisé, cassette et appareil pour la synthèse d'agents d'imagerie
EP21216335.6A Pending EP4046990A1 (fr) 2010-02-08 2011-02-08 Procédés et appareil pour la synthèse d'agents d'imagerie et leurs intermédiaires

Country Status (20)

Country Link
US (5) US8936777B2 (fr)
EP (3) EP3323810B1 (fr)
JP (3) JP6092628B2 (fr)
KR (5) KR101709372B1 (fr)
CN (3) CN113058046A (fr)
AU (3) AU2011213568B2 (fr)
BR (1) BR112012019789A2 (fr)
CA (1) CA2789044C (fr)
DK (2) DK3323810T3 (fr)
ES (2) ES2909318T3 (fr)
HK (1) HK1255702A1 (fr)
IL (2) IL221253B (fr)
MX (1) MX348958B (fr)
NO (1) NO2534136T3 (fr)
NZ (1) NZ602291A (fr)
PT (2) PT2534136T (fr)
RU (1) RU2631500C2 (fr)
SG (2) SG183134A1 (fr)
TW (4) TWI686370B (fr)
WO (1) WO2011097649A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
EP2474525B1 (fr) 2006-12-26 2020-04-15 Lantheus Medical Imaging, Inc. Ligands pour l'imagerie de l'innervation cardiaque
PT2257315T (pt) 2008-02-29 2020-01-27 Lantheus Medical Imaging Inc Agentes de contraste para aplicações incluindo imagiologia de perfusão
PT2419096T (pt) 2009-04-15 2020-02-19 Lantheus Medical Imaging Inc Estabilização de composições radiofarmacêuticas utilizando ácido ascórbico
US10109385B2 (en) 2009-09-23 2018-10-23 Abt Molecular Imaging, Inc. Dose synthesis card for use with automated biomarker production system
PT2534136T (pt) * 2010-02-08 2017-12-15 Lantheus Medical Imaging Inc Métodos para sintetizar agentes de imagiologia, e seus intermediários
CA2798488C (fr) 2010-05-11 2019-06-04 Lantheus Medical Imaging, Inc. Compositions, procedes et systemes pour la synthese et utilisation d'agents d'imagerie
US11129911B2 (en) 2011-05-05 2021-09-28 Cedars-Sinai Medical Center Assessment of coronary heart disease with carbon dioxide
CA2845308C (fr) * 2011-05-05 2021-01-26 Cedars-Sinai Medical Center Evaluation de la maladie coronarienne faisant appel au dioxyde de carbone
CN104159890B (zh) * 2011-09-09 2018-04-10 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
CA2852395C (fr) * 2011-10-21 2020-04-28 Lantheus Medical Imaging, Inc. Compositions renfermant de l'acide ascorbique et du pyridaben et des analogues de pyridaben fixes a une fraction d'imagerie et methodes associees
WO2013070471A1 (fr) 2011-11-11 2013-05-16 Lantheus Medical Imaging, Inc. Évaluation de la présence d'une fibrillation auriculaire et de la vulnérabilité à celle-ci, et autres indications sur la base d'une imagerie fondée sur les métalloprotéinases matricielles
EP2836241B1 (fr) * 2012-04-10 2019-02-20 Lantheus Medical Imaging, Inc. Procédés de synthèse d'agent radiopharmaceutique
CA2794281C (fr) * 2012-04-30 2019-07-02 Elazar A. Bienenstock Procede d'imagerie de tomographie d'emission monophotonique
WO2013172979A1 (fr) * 2012-05-14 2013-11-21 University Of Southern California Procédés et compositions destinés à l'imagerie de perfusion myocardique par tomographie par émission de positons
AU2013203000B9 (en) * 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2015021078A1 (fr) 2013-08-05 2015-02-12 Cedars-Sinai Medical Center Méthodes de réduction de lésion de reperfusion d'ischémie
JP6190240B2 (ja) 2013-10-16 2017-08-30 浜松ホトニクス株式会社 癌に対する治療効果の診断剤
US9031300B1 (en) 2013-10-25 2015-05-12 General Electric Company System and method reconstructing a nuclear medicine image using deformed attenuation image
CN107530455A (zh) * 2015-02-10 2018-01-02 Abt分子成像公司 与自动化生物标记物生产系统联用的剂量合成卡
NL2014828B1 (en) * 2015-05-20 2017-01-31 Out And Out Chemistry S P R L Method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, a device and cassette for performing this method.
CN105553594B (zh) * 2015-12-09 2018-02-16 沈阳东软医疗系统有限公司 一种pet时钟同步方法和装置
US11109819B2 (en) 2016-04-11 2021-09-07 The General Hospital Corporation System and method for quantitatively mapping mitochondrial membrane potential
JP6060302B1 (ja) * 2016-06-10 2017-01-11 日本メジフィジックス株式会社 心筋核医学画像データの解析方法及び解析装置
TWI649067B (zh) * 2017-03-01 2019-02-01 醫百科技股份有限公司 Positioning corrector
CN108129673B (zh) * 2017-12-26 2020-10-13 武汉大学 一种高灵敏度水溶性树枝状大分子f19显影剂的制备及其应用
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
CN108658868A (zh) * 2018-05-07 2018-10-16 四川大学 一种碳酸氢盐离子液体及其制备方法以及一种三氨基三硝基苯的重结晶方法
EP3671511B1 (fr) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Système et procédé de communication
CN109806822B (zh) * 2019-01-30 2021-07-30 杭州吉蕊科技有限公司 一种模块化、多功能的pet探针自动化合成系统
CN109896934A (zh) * 2019-03-08 2019-06-18 山东省药学科学院 一种高纯度2-苄氧基溴乙烷的制备方法
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
GB201919016D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare Ltd Apparatus and method for solid phase extraction
CN111333638A (zh) * 2020-03-17 2020-06-26 四川大学华西医院 18f标记的异喹啉并哒嗪酮类化合物及其合成方法和应用
JP7362561B2 (ja) * 2020-07-30 2023-10-17 富士フイルム株式会社 放射線画像処理装置、方法およびプログラム
WO2022261502A1 (fr) * 2021-06-11 2022-12-15 Jubilant Draximage Inc. Procédés d'imagerie non invasive de diagnostic d'une maladie artérielle périphérique
GB202108608D0 (en) 2021-06-16 2021-07-28 Ge Healthcare Ltd Preparation of a ph-adjusted ascorbic acid solution
GB202108605D0 (en) 2021-06-16 2021-07-28 Ge Healthcare Uk Ltd Effect of water content
CN114700006B (zh) * 2022-06-07 2023-03-24 北京先通国际医药科技股份有限公司 一种液体组合物的生产设备及其制备方法和用途
CN114716415B (zh) * 2022-06-09 2022-09-02 北京先通国际医药科技股份有限公司 生产液体组合物的设备及其制备方法和用途
CN114732918B (zh) * 2022-06-10 2022-09-13 北京先通国际医药科技股份有限公司 一种液体组合物的生产设备及其制备方法和用途
CN114773179B (zh) * 2022-06-23 2022-09-16 北京先通国际医药科技股份有限公司 一种化合物ⅰ液体组合物的制备方法、及其在心肌代谢pet显像上的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082425A1 (fr) * 2004-02-24 2005-09-09 The General Hospital Corporation Radiofluoration catalytique

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1073999A (en) 1965-01-29 1967-06-28 Ncr Co Process for forming stable images in photochromic material
US4510125A (en) 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
JPS604173A (ja) 1983-06-23 1985-01-10 Nissan Chem Ind Ltd ピリダジノン誘導体，その製造法および殺虫・殺ダニ・殺菌剤
DE3574870D1 (de) 1984-06-23 1990-01-25 Nissan Chemical Ind Ltd Verfahren zu herstellung von 2-tert.-butyl-4,5-dichloro-3(2h)-pyridazinon.
JPH07116161B2 (ja) 1984-07-04 1995-12-13 日産化学工業株式会社 ピリダジノン誘導体
JPS61130275A (ja) 1984-11-29 1986-06-18 Nissan Chem Ind Ltd ピリダジノン誘導体，その製造法および殺虫・殺ダニ・殺菌剤
DE3578304D1 (de) 1984-11-29 1990-07-26 Nissan Chemical Ind Ltd Pyridazinonderivate, deren herstellung und insektizidische, acaricidische, nematicidische, fungizidische zusammensetzungen.
CA1265798A (fr) 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h) pyridazinone, procede de preparation et agent anti-allergique le contenant
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH0641454B2 (ja) 1985-02-27 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
JPS61260018A (ja) * 1985-05-14 1986-11-18 Nissan Chem Ind Ltd 抗アレルギ−剤
YU134686A (en) 1985-07-30 1988-02-29 Nissan Chemical Ind Ltd Process for preparing new derivatives 3-(2h)-pyridazinone
JPH0739397B2 (ja) 1985-07-30 1995-05-01 日産化学工業株式会社 ピリダジノン誘導体および害虫防除剤
JPH07110815B2 (ja) 1985-11-18 1995-11-29 ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤
JPS6315974A (ja) 1986-07-09 1988-01-23 小泉コンピユ−タ−株式会社 ボ−リングゲ−ム点数表表示装置
US5252317A (en) 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5567411A (en) 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
JPS63159372A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン化合物および殺虫、殺ダニ、殺線虫剤
JPS63159374A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン誘導体および殺虫、殺ダニ、殺線虫剤
JPS63159373A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン類および殺虫、殺ダニ、殺線虫剤
DE3824210A1 (de) 1988-07-16 1990-01-18 Basf Ag 3(2h)-pyridazinonderivate zur bekaempfung von schnecken
IT1229684B (it) 1989-04-05 1991-09-06 Mini Ricerca Scient Tecnolog Piridazinoni ad attivita' insetticida ed acaricida
JPH02279676A (ja) 1989-04-19 1990-11-15 Otsuka Chem Co Ltd ピリダジノン誘導体
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5377681A (en) 1989-11-13 1995-01-03 University Of Florida Method of diagnosing impaired blood flow
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
JPH03220177A (ja) 1990-01-25 1991-09-27 Nissan Chem Ind Ltd 殺虫、殺ダニ剤組成物
WO1992017215A1 (fr) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Milieux de contraste
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
JPH04235975A (ja) 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5093105A (en) 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5306482A (en) 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
ES2150916T3 (es) 1991-08-29 2000-12-16 Mallinckrodt Medical Inc Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
US5169942A (en) 1991-11-21 1992-12-08 General Electric Company Method for making 2-(18F)fluoro-2-deoxy-D-glucose
WO1994012479A1 (fr) 1992-12-03 1994-06-09 Otsuka Kagaku Kabushiki Kaisha Derive de pyridazinone et agent insecticide et acaricide
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
WO1994021653A1 (fr) 1993-03-22 1994-09-29 General Electric Company Procede pour fabriquer le 2-fluoro-2-desoxyglucose
CA2158249A1 (fr) 1993-03-31 1994-10-13 James W. Brodack Formulations radiopharmaceutiques renfermant des reducteurs non stanneux
US5417959A (en) 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
JPH07252236A (ja) 1994-01-28 1995-10-03 Takeda Chem Ind Ltd 抗癌剤
EP0665223A1 (fr) 1994-01-28 1995-08-02 Takeda Chemical Industries, Ltd. Agents anti-tumeurs, dérivés de 3(2H)-pyrizadinone et leur préparation
AU7312694A (en) 1994-06-03 1996-01-04 Mallinckrodt Medical, Inc. Rapidly clearing technetium-99m phosphonate skeletal imaging agents
US5520904A (en) 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (fr) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions et méthodes pour l'imagerie ultrasonique dirigée
US5587491A (en) 1995-03-15 1996-12-24 Regents Of The University Of Minnesota Method for the synthesis of bis-tetrahydrofuranyl Annonaceous acetogenins
US5801228A (en) 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US5811073A (en) 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5827073A (en) 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5804161A (en) 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
AU5671699A (en) 1998-08-14 2000-03-06 Smithkline Beecham Corporation Grp receptor ligands
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
EP1119356B1 (fr) 1998-09-29 2009-08-19 Merck & Co., Inc. Antagonistes radiomarques du recepteur de la neurokinine 1
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
WO2001087354A2 (fr) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Utilisation de radioligands a petites molecules en vue de rechercher des inhibiteurs de production d'amyloide-beta et destine a l'imagerie diagnostique
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
WO2002020008A1 (fr) 2000-09-06 2002-03-14 The Scripps Research Institute Oxidoreductase d'ubiquinone utilisee comme inhibiteur de nadh
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US7344702B2 (en) * 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US7186241B2 (en) * 2001-10-03 2007-03-06 Medical Instill Technologies, Inc. Syringe with needle penetrable and laser resealable stopper
JP2005529840A (ja) 2001-10-16 2005-10-06 ヒプニオン， インコーポレイテッド Ｃｎｓ標的モジュレータを使用するｃｎｓ障害の治療
JP4530665B2 (ja) 2002-02-06 2010-08-25 ジョンズ ホプキンス ユニバーシティ 放射性標識された親油性の塩を使用することによる、ミトコンドリアのための非浸襲性の画像診断技術
EA009334B1 (ru) 2002-03-29 2007-12-28 Янссен Фармацевтика Н.В. Меченные радиоактивными изотопами производные хинолина и их применение в качестве лигандов метаботропного глутаматного рецептора
AU2003224747A1 (en) 2002-04-08 2003-10-27 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
GB0229683D0 (en) 2002-12-20 2003-01-29 Imaging Res Solutions Ltd Preparation of radiopharmaceuticals
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2005007632A1 (fr) 2003-07-18 2005-01-27 Pharmacia Corporation Pyridazinones substituees utiles comme inhibiteurs de p38
CA2783275A1 (fr) 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Compositions radiopharmaceutiques stables et methodes pour leur preparation
GB0317920D0 (en) 2003-07-31 2003-09-03 Amersham Plc Solid-phase synthesis
US7927616B2 (en) 2004-01-16 2011-04-19 Thomas T. Yamashita Pesticide compositions and methods for their use
WO2005085200A1 (fr) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Dérivé pyridone
AT500838B1 (de) 2004-04-20 2007-11-15 Veterinaermedizinische Uni Wie Multiple hse
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
US7534418B2 (en) 2004-12-10 2009-05-19 The Regents Of The University Of Michigan Imaging agents
KR100789847B1 (ko) 2004-12-15 2007-12-28 (주)퓨쳐켐 알코올 용매하에서 유기플루오로 화합물의 제조방법
EP1893244A4 (fr) 2005-06-23 2009-06-24 Univ Emory Agents pour l'imagerie
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
JP2007112725A (ja) * 2005-10-18 2007-05-10 Inst Nuclear Energy Research Rocaec 無支持体の１８Ｆで標識したアミノ酸Ｏ−（２−［１８Ｆ］ｆｌｕｏｒｏｅｔｈｙｌ）−Ｌ−Ｔｙｒｏｓｉｎｅの製造方法。
GB0524851D0 (en) * 2005-12-06 2006-01-11 Ge Healthcare Ltd Radiolabelling method using polymers
US7871623B2 (en) * 2005-12-21 2011-01-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for imaging pain and stress in vivo
EP2023919A4 (fr) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc Composés et sondes amyloïdes de ceux-ci pour des utilisations thérapeutiques et en imagerie
US10328164B2 (en) 2006-06-21 2019-06-25 Ge Healthcare Limited Radiopharmaceutical products
WO2008022979A1 (fr) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh NOUVEAUX DÉRIVÉS DE LA PYRIDONE PRÉSENTANT UNE ACTIVITÉ ANTAGONISTE de MCH ET MÉDICAMENTS COMPRENANT CES COMPOSÉS
WO2009110894A1 (fr) * 2008-03-05 2009-09-11 Rhino Technologies Llc Boulon en spirale pouvant être tendu avec écrou en résine et procédé apparenté
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2474525B1 (fr) 2006-12-26 2020-04-15 Lantheus Medical Imaging, Inc. Ligands pour l'imagerie de l'innervation cardiaque
JP5504563B2 (ja) 2006-12-27 2014-05-28 住友化学株式会社 組成物及び該組成物を用いてなる発光素子
CA2683433C (fr) 2007-04-05 2016-10-11 Siemens Medical Solutions Usa, Inc. Agents pour imagerie de l'hypoxie a base de nitro-imidazoles
GB0718386D0 (en) 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
CN101157649A (zh) * 2007-10-23 2008-04-09 江苏省原子医学研究所 18F－Fallypride自动化合成的方法
KR101068835B1 (ko) * 2007-10-26 2011-09-30 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를가지는 이소인돌론 화합물 및 이의 제조 방법
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
WO2009103478A1 (fr) 2008-02-19 2009-08-27 Boehringer Ingelheim International Gmbh Dérivés de pyridone et de pyridazinone comme antagonistes de la mch
WO2010011367A2 (fr) 2008-02-22 2010-01-28 Illinois Institute Of Technology Ligands bimodaux avec des fractions de liaison macrocycliques et acycliques, complexes et compositions les comprenant, et procédés d’utilisation
PT2257315T (pt) * 2008-02-29 2020-01-27 Lantheus Medical Imaging Inc Agentes de contraste para aplicações incluindo imagiologia de perfusão
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2009146388A1 (fr) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Procédés à base de voxel destinés à évaluer des sujets au moyen de la tomographie par émission de positons
KR20110121632A (ko) * 2009-02-25 2011-11-07 포컬 테크놀러지스 코퍼레이션 광섬유 로터리 조인트에 사용되는 저손실 시준기
EP2406233B1 (fr) 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Analogues d'aza-pyridone utiles en tant que antagonistes des récepteurs de l'hormone concentrant la mélanine
PT2419096T (pt) 2009-04-15 2020-02-19 Lantheus Medical Imaging Inc Estabilização de composições radiofarmacêuticas utilizando ácido ascórbico
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
KR20120051641A (ko) 2009-07-11 2012-05-22 바이엘 파마 악티엔게젤샤프트 비-극성 및 극성 이탈기
PT2534136T (pt) 2010-02-08 2017-12-15 Lantheus Medical Imaging Inc Métodos para sintetizar agentes de imagiologia, e seus intermediários
CA2798488C (fr) 2010-05-11 2019-06-04 Lantheus Medical Imaging, Inc. Compositions, procedes et systemes pour la synthese et utilisation d'agents d'imagerie
DE102010036356A1 (de) * 2010-07-12 2012-01-12 Abx Advanced Biochemical Compounds Gmbh Vorrichtung zur Synthese radioaktiv markierter Verbindungen
JP5842594B2 (ja) 2010-12-27 2016-01-13 住友化学株式会社 ピリダジノン化合物、それを含有する除草剤及び有害節足動物防除剤
CN102336741B (zh) 2011-07-06 2013-04-10 北京师范大学 氟-18标记的心肌灌注显像剂及其制备方法和应用
CN104159890B (zh) 2011-09-09 2018-04-10 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
CA2852395C (fr) 2011-10-21 2020-04-28 Lantheus Medical Imaging, Inc. Compositions renfermant de l'acide ascorbique et du pyridaben et des analogues de pyridaben fixes a une fraction d'imagerie et methodes associees
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US20150246143A1 (en) 2012-08-13 2015-09-03 Lantheus Medical Imaging, Inc. System and method for quantitative mapping of mitochondrial complex 1
WO2014047446A1 (fr) 2012-09-21 2014-03-27 The General Hospital Corporation Système et procédé pour une tomographie par émission de positons (tep) cardiaque au repos/à l'effort à balayage unique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082425A1 (fr) * 2004-02-24 2005-09-09 The General Hospital Corporation Radiofluoration catalytique

Also Published As

Publication number Publication date
PT3323810T (pt) 2022-04-14
DK3323810T3 (da) 2022-03-28
CN102858752B (zh) 2018-10-16
US20210187131A1 (en) 2021-06-24
EP3323810A2 (fr) 2018-05-23
EP4046990A1 (fr) 2022-08-24
EP2534136A2 (fr) 2012-12-19
TW201741288A (zh) 2017-12-01
TWI589302B (zh) 2017-07-01
US20150165074A1 (en) 2015-06-18
IL263543A (en) 2019-01-31
AU2018201916C1 (en) 2020-10-29
IL221253B (en) 2018-12-31
KR20120130293A (ko) 2012-11-30
NO2534136T3 (fr) 2018-02-03
TW201706252A (zh) 2017-02-16
IL263543B (en) 2019-08-29
HK1255702A1 (zh) 2019-08-23
CA2789044A1 (fr) 2011-08-11
KR20190067255A (ko) 2019-06-14
KR20180055933A (ko) 2018-05-25
JP6092628B2 (ja) 2017-03-08
KR20210132243A (ko) 2021-11-03
EP3323810B1 (fr) 2022-01-05
US20170258947A1 (en) 2017-09-14
RU2631500C2 (ru) 2017-09-25
TWI660947B (zh) 2019-06-01
RU2012138262A (ru) 2014-03-20
CN109200296A (zh) 2019-01-15
WO2011097649A2 (fr) 2011-08-11
JP6254126B2 (ja) 2017-12-27
NZ602291A (en) 2014-10-31
CN113058046A (zh) 2021-07-02
US9603951B2 (en) 2017-03-28
KR101709372B1 (ko) 2017-02-22
IL221253A0 (en) 2012-10-31
SG183134A1 (en) 2012-09-27
AU2011213568B2 (en) 2016-05-12
MX2012009174A (es) 2012-11-12
CN109200296B (zh) 2021-12-14
US20190290788A1 (en) 2019-09-26
JP6685269B2 (ja) 2020-04-22
TWI686370B (zh) 2020-03-01
AU2018201916B2 (en) 2020-04-30
ES2909318T3 (es) 2022-05-06
BR112012019789A2 (pt) 2016-08-09
EP3323810A3 (fr) 2018-07-04
TW201843128A (zh) 2018-12-16
EP2534136B1 (fr) 2017-09-06
US10022462B2 (en) 2018-07-17
KR20170033873A (ko) 2017-03-27
US20130064769A1 (en) 2013-03-14
CA2789044C (fr) 2020-09-15
US8936777B2 (en) 2015-01-20
US10842892B2 (en) 2020-11-24
JP2013518913A (ja) 2013-05-23
TW201134491A (en) 2011-10-16
CN102858752A (zh) 2013-01-02
JP2018076328A (ja) 2018-05-17
KR102438133B1 (ko) 2022-08-31
MX348958B (es) 2017-07-04
TWI664169B (zh) 2019-07-01
DK2534136T3 (en) 2017-12-04
SG10201500929XA (en) 2015-04-29
AU2016213781A1 (en) 2016-09-01
AU2018201916A1 (en) 2018-04-12
ES2651466T3 (es) 2018-01-26
AU2011213568A1 (en) 2012-09-27
JP2016029059A (ja) 2016-03-03
WO2011097649A3 (fr) 2011-12-15
PT2534136T (pt) 2017-12-15

Similar Documents

Publication Publication Date Title
IL263543B (en) Methods and devices for synthesizing imaging factors, and their intermediates
EP2633678A4 (fr) Appareil de type téléphone microscope ou cellscope et procédés d'imagerie
GB2485534B (en) Imaging recording apparatus
EP2555686A4 (fr) Procédé et appareil pour imagerie ultrasonore
EP2581028A4 (fr) Appareil d'imagerie pour endoscopes
EP2531109A4 (fr) Appareil d'imagerie dentaire
EP2544898A4 (fr) Appareil de formation d'image
GB2481971B (en) Apparatus & method
EP2605053A4 (fr) Appareil d'imagerie
EP2548083A4 (fr) Appareil de formation d'image
EP2571250A4 (fr) Dispositif d'imagerie
EP2596320A4 (fr) Procédé et appareil d'imagerie
EP2587665A4 (fr) Appareil amplificateur
GB201012037D0 (en) Apparatus & method
EP2747410A4 (fr) Dispositif d'imagerie
GB0804629D0 (en) Imaging apparatus & method
GB201006180D0 (en) Imaging apparatus
HK1176691A1 (en) Imaging apparatus
EP2645404A4 (fr) Appareil d'exposition
EP2590024A4 (fr) Procédé et appareil d'imagerie
HK1172760A1 (en) Imaging apparatus
GB201012231D0 (en) Apparatus & Method
EP2401952A4 (fr) Appareil d'endoscopie
HK1171139A1 (en) Imaging apparatus and imaging method
HK1159905A1 (en) Imaging apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120907

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130625

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 237/14 20060101AFI20130619BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179950

Country of ref document: HK

17Q First examination report despatched

Effective date: 20150611

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170321

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 925733

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011041322

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20171127

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2534136

Country of ref document: PT

Date of ref document: 20171215

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171206

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2651466

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20170906

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180106

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170403370

Country of ref document: GR

Effective date: 20180518

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011041322

Country of ref document: DE

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1179950

Country of ref document: HK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170906

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170906

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 925733

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170906

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230521

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20231221

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240220

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240221

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240219

Year of fee payment: 14

Ref country code: IE

Payment date: 20240219

Year of fee payment: 14

Ref country code: ES

Payment date: 20240325

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240220

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20240219

Year of fee payment: 14

Ref country code: DE

Payment date: 20240219

Year of fee payment: 14

Ref country code: GB

Payment date: 20240219

Year of fee payment: 14

Ref country code: CH

Payment date: 20240301

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240219

Year of fee payment: 14

Ref country code: NO

Payment date: 20240222

Year of fee payment: 14

Ref country code: IT

Payment date: 20240228

Year of fee payment: 14

Ref country code: FR

Payment date: 20240221

Year of fee payment: 14

Ref country code: DK

Payment date: 20240223

Year of fee payment: 14

Ref country code: BE

Payment date: 20240219

Year of fee payment: 14